FDMT Stock Summary and Trading Ideas (4D Molecular Therapeutics | NASDAQ:FDMT)

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

4D Molecular Therapeutics trades on the NASDAQ stock market under the symbol FDMT.

As of February 27, 2026, FDMT stock price was flat at $9.66 with 719,575 million shares trading.

FDMT has a beta of 1.32, meaning it tends to be more sensitive to market movements. FDMT has a correlation of 0.07 to the broad based SPY ETF.

FDMT has a market cap of $492.74 million. This is considered a Small Cap stock.

Last quarter 4D Molecular Therapeutics reported $90,000 in Revenue and -$1.01 earnings per share. This fell short of revenue expectation by $-555,800 and missed earnings estimates by -$.01.

In the last 3 years, FDMT traded as high as $36.25 and as low as $2.24.

The top ETF exchange traded funds that FDMT belongs to (by Net Assets): VTI, XBI, IWM, VXF, IBB.

FDMT has outperformed the market in the last year with a price return of +115.6% while the SPY ETF gained +18.5%. However, in the short term, FDMT had mixed performance relative to the market. It has underperformed in the last 3 months, returning -12.1% vs +1.2% return in SPY. But in the last 2 weeks, FDMT shares have fared better than the market returning +3.3% compared to SPY +0.6%.

FDMT support price is $9.23 and resistance is $10.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FDMT shares will trade within this expected range on the day.